While low-volatility stocks offer a sense of security, they are not a guaranteed path to growth. We analyze one company with a stable profile and promising outlook, alongside two others where caution may be warranted despite their calm trading history.
Heineken launches a global marketing initiative celebrating shared passions in sports and music, aiming to foster real-world connections amid declining U.S. sales and a competitive import beer market.
CNBC's Jim Cramer suggests Intel shares could surge significantly, as the chipmaker's strategic overhaul and analyst upgrades fuel investor optimism amid a 140% yearly gain.
Cocoa prices staged a modest technical rebound on Friday, halting a month-long slide that had pushed contracts to their lowest levels in over two years. The move higher, driven by short-covering in an oversold market, comes amid a complex backdrop of abundant near-term supplies, weakening demand, and a tightening longer-term outlook.
The U.S. rig count saw a marginal increase this week, yet remains significantly below last year's levels as crude production dips and completions activity sends conflicting signals.
While mid-cap companies often represent a sweet spot between growth and stability, heightened competition and shifting market dynamics are putting pressure on some notable names. Here’s a closer look at three stocks where caution may be warranted.
The third-quarter earnings season reveals a sector at a crossroads. While government and technical consulting firms like Jacobs Solutions benefit from long-term structural trends, their latest financial results and market reactions paint a complex picture of resilience and recalibration.
Crude oil and gasoline prices advanced on Friday, supported by persistent geopolitical risks in the Middle East and ongoing supply constraints, though gains were tempered by a stronger dollar and diplomatic signals.
As speculation intensifies over a potential acquisition of Warner Bros. Discovery by Netflix, short sellers are rapidly retreating from the stock, signaling market confidence in both the deal's completion and regulatory approval.
In a significant diplomatic move, Lebanon's Cabinet has approved an agreement to repatriate hundreds of Syrian prisoners, addressing a major point of contention as the two nations navigate a new political reality following the 2024 ouster of Bashar al-Assad.
The historic Farmers' Almanac, famed for its secret weather formula, has been acquired by digital media company Unofficial Networks. The move saves the publication from shuttering, relocates its operations from Maine to New York, and promises a digital-first revival alongside a planned return to print.
Chinese autonomous driving leader WeRide has launched its proprietary general-purpose simulation model, Genesis, designed to bridge the gap between real-world data and virtual testing. The platform promises to drastically cut development time and costs for AV systems, from advanced driver-assistance features to fully autonomous robotaxis.
Regeneron Pharmaceuticals is positioning its experimental obesity drug, olatorepatide, as a potential game-changer by combining significant weight loss with a dramatic reduction in 'bad' cholesterol. The company believes this dual benefit could carve out a unique niche in the competitive $150 billion market, currently led by Novo Nordisk and Eli Lilly.
Following a rupture in their longstanding security alliance, French President Emmanuel Macron and Chadian leader Mahamat Idriss Deby Itno have agreed to reset bilateral relations, placing future cooperation squarely in the economic and developmental sphere.
Federal prosecutors unseal indictments against the CEO and senior vice president of First Brands Group, alleging a complex financial fraud that contributed to the company's recent bankruptcy.
Exclusive: A newly revealed State Department cable directs embassies worldwide to audit all assistance programs against stringent new rules prohibiting funding for groups involved in abortion services, diversity initiatives, and gender identity advocacy, expanding a long-contested policy to nearly $30 billion in foreign aid.
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
As global economic headwinds persist, UK investors are turning to dividend-paying stocks for portfolio resilience. We analyze three FTSE-listed companies with strong income credentials and growth potential for the coming year.
Shares of FMC Corporation have surged over 13% in the past month, sparking debate among investors. While the short-term bounce offers relief, it contrasts sharply with a punishing 70% decline over the past year. Analysts and investors are now weighing whether the current valuation gap represents a genuine opportunity or a reflection of deep-seated challenges.
Having cemented its status as a trillion-dollar titan on the back of the AI boom, semiconductor leader Broadcom now sets its sights on sustained growth. We analyze the drivers behind its surge and what investors can expect in the coming year.
